Analysts See $-1.47 EPS for Aerie Pharmaceuticals, Inc. (AERI)

February 23, 2018 - By Michael Collier

 Analysts See $ 1.47 EPS for Aerie Pharmaceuticals, Inc. (AERI)
Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It is positive, as 14 investors sold Aerie Pharmaceuticals, Inc. shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported.
Waddell And Reed invested in 463,354 shares or 0.05% of the stock. 25,000 were reported by Neuberger Berman Grp Incorporated Ltd Liability Com. Los Angeles Mngmt Equity Rech has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Millennium Mngmt Limited Com reported 264,798 shares. Columbus Circle Invsts holds 0.43% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 519,806 shares. Swiss National Bank & Trust invested in 50,300 shares. Century Incorporated reported 24,236 shares or 0% of all its holdings. Nationwide Fund Advsr holds 0.01% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 71,609 shares. Axa accumulated 205,717 shares or 0.04% of the stock. Geode Management Ltd, Massachusetts-based fund reported 309,231 shares. California Pub Employees Retirement Sys reported 7,525 shares stake. Hanseatic Mngmt holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 16 shares. Credit Suisse Ag invested 0.01% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Tudor Et Al invested 0.01% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Savings Bank Of New York Mellon accumulated 550,275 shares.

Analysts expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report $-1.47 EPS on March, 6.They anticipate $0.60 EPS change or 68.97 % from last quarter’s $-0.87 EPS. After having $-0.89 EPS previously, Aerie Pharmaceuticals, Inc.’s analysts see 65.17 % EPS growth. The stock increased 2.19% or $1.15 during the last trading session, reaching $53.7. About 174,721 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since February 23, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 47 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Tuesday, September 20. The rating was maintained by Canaccord Genuity on Wednesday, August 16 with “Buy”. Cowen & Co maintained the shares of AERI in report on Thursday, October 5 with “Buy” rating. JMP Securities initiated Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Wednesday, September 9 with “Market Outperform” rating. The firm has “Buy” rating by Mizuho given on Wednesday, September 6. Needham maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Friday, September 15. Needham has “Buy” rating and $65.0 target. RBC Capital Markets maintained it with “Outperform” rating and $50 target in Wednesday, November 4 report. The firm earned “Buy” rating on Monday, December 18 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, September 17. The company was maintained on Thursday, September 15 by Cantor Fitzgerald.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.11 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Nasdaq.com which released: “Aerie Pharmaceuticals Breaks Below 200-Day Moving Average – Notable for AERI” on January 31, 2018, also Businesswire.com with their article: “Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of …” published on February 01, 2018, Businesswire.com published: “Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel” on February 20, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: Nasdaq.com and their article: “Can Rhopressa’s Approval Drive Aerie (AERI) in Q4 Earnings?” published on February 23, 2018 as well as Businesswire.com‘s news article titled: “Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales …” with publication date: February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: